喉鳞状细胞癌中IL-18的表达与临床病理的关系及西妥昔单抗对其表达的影响

Relationship between interleukin 18 expression in laryngeal squamous cell carcinoma and clinical pathology as well as the effect of cetuximab on its expression

目的:探讨喉鳞状细胞癌组织中白细胞介素-18(IL-18)的表达与临床病理的关系及西妥昔单抗对其表达的影响。方法:选择喉鳞状细胞癌患者40例为研究组,选择声带息肉患者40例和健康者40例为对照组。对喉鳞状细胞癌临床病理进行统计学分析,检测西妥昔单抗作用前和作用后外周血单核细胞中IL-18、干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平。结果:喉鳞状细胞癌组IL-18检测值高于癌旁组织和声带息肉,差异具有统计学意义(P<0.05);喉鳞状细胞癌组IL-18阳性率高于癌旁组织和息肉组织,差异具有统计学意义(P<0.01);喉鳞状细胞癌组IL-18的表达与原发灶分期、分化程度、淋巴结转移有关,差异具有统计学意义(P<0.05);西妥昔单抗作用前IL-18水平明显高于对照组,西妥昔单抗作用后IL-18水平明显较作用前下降,差异有统计学意义(P<0.01);西妥昔单抗作用后喉鳞状细胞癌患者PBMCs上清中IFN-γ、TNF-α、IL-6的水平明显低于作用前,差异有统计学意义(P<0.01)。结论:喉鳞状细胞癌中IL-18可出现高表达;IL-18的表达参与了喉鳞状细胞癌的发生及进展;IL-18可能是通过调控IFN-γ、TNF-α、IL-6等指标的表达参与喉鳞状细胞癌的发生及进展;IL-18可以作为喉鳞状细胞癌治疗的一个靶点,西妥昔单抗可以抑制IL-18的表达。

Objective： To explore the relationship between Interleukin 18 （IL-18） expression in laryngeal squamous cell carcinoma and clinical pathology as well as the effect of cetuximab on its expression. Methods： 40 cases of patients with laryn- geal squamous cell carcinoma were chosen as research group, 40 cases of patients with vocal cord polyp and 40 healthy volunteers were chosen as control group. Statistical analysis was carried out on clinical pathology of laryngeal squamous cell carcino- ma. IL-18, IFN-γ, TNF-aand IL-6 levels in peripheral blood mononuclear cells before and after cetuximab treatment were detected. Results： Detected IL-18 values of laryngeal squamous cell carcinoma group were higher than those of adjacent cancer tissue and vocal cord polyps （P〈0.05）. IL-18 positive rate （75.0%） of laryngeal squamous cell carcinoma group was higher than that of adjacent cancer tissue （47.5%） and polyp tissue （37.5%） （P〈0.01） IL-18 expressions of laryngeal squamous cell carcinoma group were related to primary lesion staging, differentiation degree and lymph node metastasis （P〈0.05）. Before cetuximab treatment, IL-18 levels were significantly higher than those of control group （P〈0.01）, but after cetuximab treatment, IL-18 levels significantly decreased （P〈0.01）. After cetuximab treatment, IFN-γ, TNF-aand IL 6 levels in PBMCs supernatant of patients with laryngeal squamous cell carcinoma were significantly lower than that before treatment （P〈 0.01）. Conclusion： IL-18 can he highly expressed in laryngeal squamous cell carcinoma. IL-18 expression is involved in the occurrence and progression of laryngeal squamous cell carcinoma through regulating expressions of IFN-γ, TNF-aand IL-6 indicating IL-18 can be used as a target of laryngeal squamous cell carcinoma treatment, and cetuximah can inhibit IL-18 expression.